ClinicalTrials.Veeva

Menu

Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose

Maastricht University Medical Centre (MUMC) logo

Maastricht University Medical Centre (MUMC)

Status

Completed

Conditions

Glycemic Control
Type 2 Diabetes

Treatments

Dietary Supplement: Sucrose consumption
Dietary Supplement: water consumption

Study type

Interventional

Funder types

Other

Identifiers

NCT00821665
07-3-004

Details and patient eligibility

About

Hyperglycemia forms a direct and independent risk factor for the development of cardiovascular co-morbidities in type 2 diabetes. Consumption of sucrose-sweetened soft drinks might further increase the prevalence of hyperglycemic episodes.

The objective of the study was to assess glycemic control in type 2 diabetes patients and healthy lean and obese controls under strict dietary standardization but otherwise free living conditions, with and without the consumption of soft drinks.

Enrollment

39 patients

Sex

Male

Ages

40 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Lean NGT Group

  • Normoglycemic (according to 2006 ADA guidelines)
  • BMI < 27 kg/m2

Obese NGT Group

  • Normoglycemic
  • BMI 30- 35 kg/m2

Obese type 2 diabetes Group

  • BMI 30- 35 kg/m2
  • Oral blood glucose lowering medication

Exclusion criteria

  • Exogenous insulin use
  • Cardiac disease (any cardiac event in the last 5 years)
  • HbA1c >10%
  • Microalbuminuria: albumin:creatinine ratio >2,5

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

39 participants in 2 patient groups, including a placebo group

Sucrose
Experimental group
Description:
Sucrose
Treatment:
Dietary Supplement: Sucrose consumption
Water
Placebo Comparator group
Description:
Water
Treatment:
Dietary Supplement: water consumption

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems